tisagenlecleucel (Kymriah) Report issue

Cell therapy Orphan Drug FDA Approved FDA Breakthrough Therapy FDA

Active Ingredient History

NOW
  • Now
Tisagenlecleucel, sold under the brand name Kymriah, is a CAR T cells medication for the treatment of B-cell acute lymphoblastic leukemia (ALL) which uses the body's own T cells to fight cancer.   Wikipedia

More Chemistry

Drug Pricing (per unit)

United States

$28355.5920 - $47394.9750
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

tisagenlecleucel

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue